Target speciesHorses
Indications for use, specifying the target species
Treatment of acute inflammatory musculoskeletal disorders in horses
Contraindications
Do not exceed the stated dose or duration of treatment.
Do not administer other NSAIDs or glucocorticosteroids concurrently or within 24 hours of each other.
Do not use in animals suffering from cardiac, hepatic or renal disease.
Do not use in animals suspected of having gastrointestinal ulceration or bleeding.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in dehydrated or hypovolaemic animals, except in the case of endotoxaemia or septic shock, as there is a potential risk of increased renal toxicity.
Do not use in animals suffering from chronic musculoskeletal disorders.
Special warnings for each target species
Use of the veterinary medicinal product may lead to temporary relief due to its ameliorating effects on inflammatory signs. This may appear as effective treatment of the underlying disease.
The cause of the underlying inflammatory condition should be determined and treated with appropriate concomitant therapy.
Special precautions for use
Special precautions for use in animals
Animals should be rested and a sufficient supply of drinking water has to be ensured during the course of treatment with the veterinary medicinal product.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
This product may cause serious adverse effects when ingested, particularly by children. Keep the product stored in a closed cabinet.
This product may cause hypersensitivity (allergic) reactions. Avoid skin contact with this product. Wear gloves during application. If you have known hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs), do not handle the product. In case of accidental contact with the skin wash exposed area immediately with plenty of water and soap. Hypersensitivity reactions may be serious. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips or eyes or difficulty with breathing, are more serious symptoms and require urgent medical attention.
This product can cause eye-irritation. Avoid contact with the eyes. If the product comes into contact with the eyes, rinse immediately with plenty of water and seek medical advice.
Adverse reactions (frequency and seriousness)
As for all non-steroidal anti-inflammatory drugs, flunixin may damage the gastrointestinal mucosa and may cause renal damage particularly in hypovolemic and hypotensive conditions, e.g. during surgery. In very rare cases allergic reactions (allergic skin reactions, anaphylaxis) may occur after administration of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy and lactation
Do not use in pregnant mares since reproductive studies have not been conducted in horses.
Interaction with other medicinal products and other forms of interaction
Concurrent administration of potentially nephrotoxic drugs, particularly aminoglycosides, should be avoided. Some NSAIDs may be highly bound to plasma proteins and may compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations which can lead to toxic effects.
Prior or concurrent administration of steroidal or other non-steroidal anti-inflammatory drugs is not recommended since they may enhance adverse reactions.
Do not use concurrently with the inhalation anesthetic methoxyfluran because of the potential risk of nephrotoxicity.
Flunixin may reduce the effect of some anti-hypertensive medicinal products, such as diuretics, angiotensin conversion enzyme (ACE) inhibitors, and beta blockers, by inhibition of prostaglandin synthesis.
Amounts to be administered and administration route
For oral administration only.
1.1 mg flunixin per kg bodyweight once daily for a maximum of 5 days according to clinical response.
Each syringe delivers 1650 mg of flunixin, sufficient to treat 1500 kg bodyweight corresponding to a three days treatment for a 500 kg horse. The syringe is calibrated in 100 kg increments to facilitate dosing of horses of different weights.
Make sure the horse's mouth contains no feed. Insert the syringe into the horse's mouth at the interdental space. Advance the plunger as far as it will go, depositing the medication on the base of the tongue.
Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of overdose, signs of toxicity such as gastrointestinal disorders and adverse reactions listed in section 4.6 can occur. In this case, the drug should be discontinued immediately and the animals treated symptomatically.
Withdrawal period(s)
Meat and offal: 15 days.
Not authorised for use in animals producing milk for human consumption.
Pharmacological particulars
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids, fluxinin.
Pharmacodynamic properties
Flunixin meglumine is a potent non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities. It acts as a reversible non-selective inhibitor of the enzyme cyclo-oxygenase (both COX 1 and COX 2 forms) reducing the synthesis of eicosanoids involved in tissue inflammation, central pyresis and pain. Flunixin also inhibits the production of thromboxane, a potent platelet pro-aggregator and vasoconstrictor which is released during blood clotting.
Although flunixin has no direct effect on endotoxins, it reduces prostaglandin production and hence the effects of the prostaglandin cascade that is part of the complex processes involved in the development of endotoxic shock.
Pharmacokinetic particulars
After oral administration of the veterinary medicinal product to horses at a dose of 1.1 mg flunixin / kg body weight maximal plasma concentrations of 4.7 (± 1.1) µg/ml were reached after approximately 1.5 hours. The AUCi of flunixin was 26.2 (± 5.2) µg.hr/ml and elimination took place with a half-life of around 6 hours.
Compared to intravenous administration, a bioavailability of approximately 80 % is achieved. Flunixin strongly binds to proteins and accumulates in the inflammatory exudate, resulting in delayed elimination.
Pharmaceutical particulars
List of excipients
Silica, colloidal anhydrous
Propylene glycol
Titanium dioxide (E171)
Xanthan gum
Aluminium Magnesium Silicate
Sorbitol, liquid (crystallising)
Apple flavour FL02791
Purified water
Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 3 months.
Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
Nature and composition of immediate packaging
White high-density polyethylene syringe barrel and dial-a-dose plunger with low-density polyethylene cap, containing 33 grams of paste. The plunger is graduated to give set doses corresponding to 100 kg bodyweight per graduation. See also section 4.9.
Marketing presentations:
Box of 1 oral syringe.
Box of 2 oral syringes.
Box of 3 oral syringes.
Box of 6 oral syringes.
Box of 12 oral syringes.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Indications for use, specifying the target species
Treatment of acute inflammatory musculoskeletal disorders in horses
Contraindications
Do not exceed the stated dose or duration of treatment.
Do not administer other NSAIDs or glucocorticosteroids concurrently or within 24 hours of each other.
Do not use in animals suffering from cardiac, hepatic or renal disease.
Do not use in animals suspected of having gastrointestinal ulceration or bleeding.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in dehydrated or hypovolaemic animals, except in the case of endotoxaemia or septic shock, as there is a potential risk of increased renal toxicity.
Do not use in animals suffering from chronic musculoskeletal disorders.
Special warnings for each target species
Use of the veterinary medicinal product may lead to temporary relief due to its ameliorating effects on inflammatory signs. This may appear as effective treatment of the underlying disease.
The cause of the underlying inflammatory condition should be determined and treated with appropriate concomitant therapy.
Special precautions for use
Special precautions for use in animals
Animals should be rested and a sufficient supply of drinking water has to be ensured during the course of treatment with the veterinary medicinal product.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
This product may cause serious adverse effects when ingested, particularly by children. Keep the product stored in a closed cabinet.
This product may cause hypersensitivity (allergic) reactions. Avoid skin contact with this product. Wear gloves during application. If you have known hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs), do not handle the product. In case of accidental contact with the skin wash exposed area immediately with plenty of water and soap. Hypersensitivity reactions may be serious. If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips or eyes or difficulty with breathing, are more serious symptoms and require urgent medical attention.
This product can cause eye-irritation. Avoid contact with the eyes. If the product comes into contact with the eyes, rinse immediately with plenty of water and seek medical advice.
Adverse reactions (frequency and seriousness)
As for all non-steroidal anti-inflammatory drugs, flunixin may damage the gastrointestinal mucosa and may cause renal damage particularly in hypovolemic and hypotensive conditions, e.g. during surgery. In very rare cases allergic reactions (allergic skin reactions, anaphylaxis) may occur after administration of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy and lactation
Do not use in pregnant mares since reproductive studies have not been conducted in horses.
Interaction with other medicinal products and other forms of interaction
Concurrent administration of potentially nephrotoxic drugs, particularly aminoglycosides, should be avoided. Some NSAIDs may be highly bound to plasma proteins and may compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations which can lead to toxic effects.
Prior or concurrent administration of steroidal or other non-steroidal anti-inflammatory drugs is not recommended since they may enhance adverse reactions.
Do not use concurrently with the inhalation anesthetic methoxyfluran because of the potential risk of nephrotoxicity.
Flunixin may reduce the effect of some anti-hypertensive medicinal products, such as diuretics, angiotensin conversion enzyme (ACE) inhibitors, and beta blockers, by inhibition of prostaglandin synthesis.
Amounts to be administered and administration route
For oral administration only.
1.1 mg flunixin per kg bodyweight once daily for a maximum of 5 days according to clinical response.
Each syringe delivers 1650 mg of flunixin, sufficient to treat 1500 kg bodyweight corresponding to a three days treatment for a 500 kg horse. The syringe is calibrated in 100 kg increments to facilitate dosing of horses of different weights.
Make sure the horse's mouth contains no feed. Insert the syringe into the horse's mouth at the interdental space. Advance the plunger as far as it will go, depositing the medication on the base of the tongue.
Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of overdose, signs of toxicity such as gastrointestinal disorders and adverse reactions listed in section 4.6 can occur. In this case, the drug should be discontinued immediately and the animals treated symptomatically.
Withdrawal period(s)
Meat and offal: 15 days.
Not authorised for use in animals producing milk for human consumption.
Pharmacological particulars
Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids, fluxinin.
Pharmacodynamic properties
Flunixin meglumine is a potent non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities. It acts as a reversible non-selective inhibitor of the enzyme cyclo-oxygenase (both COX 1 and COX 2 forms) reducing the synthesis of eicosanoids involved in tissue inflammation, central pyresis and pain. Flunixin also inhibits the production of thromboxane, a potent platelet pro-aggregator and vasoconstrictor which is released during blood clotting.
Although flunixin has no direct effect on endotoxins, it reduces prostaglandin production and hence the effects of the prostaglandin cascade that is part of the complex processes involved in the development of endotoxic shock.
Pharmacokinetic particulars
After oral administration of the veterinary medicinal product to horses at a dose of 1.1 mg flunixin / kg body weight maximal plasma concentrations of 4.7 (± 1.1) µg/ml were reached after approximately 1.5 hours. The AUCi of flunixin was 26.2 (± 5.2) µg.hr/ml and elimination took place with a half-life of around 6 hours.
Compared to intravenous administration, a bioavailability of approximately 80 % is achieved. Flunixin strongly binds to proteins and accumulates in the inflammatory exudate, resulting in delayed elimination.
Pharmaceutical particulars
List of excipients
Silica, colloidal anhydrous
Propylene glycol
Titanium dioxide (E171)
Xanthan gum
Aluminium Magnesium Silicate
Sorbitol, liquid (crystallising)
Apple flavour FL02791
Purified water
Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 3 months.
Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.
Nature and composition of immediate packaging
White high-density polyethylene syringe barrel and dial-a-dose plunger with low-density polyethylene cap, containing 33 grams of paste. The plunger is graduated to give set doses corresponding to 100 kg bodyweight per graduation. See also section 4.9.
Marketing presentations:
Box of 1 oral syringe.
Box of 2 oral syringes.
Box of 3 oral syringes.
Box of 6 oral syringes.
Box of 12 oral syringes.
Not all pack sizes may be marketed.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Shipping charges mainland GB zone1
| Value | Weight | Delivery Charge |
| Over £49.00 | Any Weight | FREE |
| Under £49.00 | No weight limit | £4.50 |
| Under £49.00 | Under 250 grams | £3.49 |
Most orders are despatched the same day and standard delivery is 3 to 5 working days from despatch. FAST Expedited options are available at extra cost - these usually arrive in 24-48hrs from dispatch but delays are possible during busy periods.
Postcodes outside of Zone 1 (including some areas within mainland UK) may incur extra carriage charges due to surcharges imposed by the couriers. These will be calculated on the website at the checkout.
NB: Orders placed with faster delivery must be placed before 13:00 to ensure same day dispatch (excluding weekends and bank holidays). Please also check on the product page that the items ordered show 'In Stock' otherwise your order will be delayed until the stock becomes available, which in most cases will only be 24hrs.
Estimated "Usually shipped in" information is shown against most products
Overseas orders
We no longer send goods outside of the UK.
Prescription Items
Prescription items will be sent on receipt of a legally valid signed and dated prescription.
Pick up
We offer a pickup service for orders placed over the phone.
Please ring us on 01833 641112 for more information.
Refrigerated Items
- Refrigerated lines Packaging Cost: Despatched with Woolcool Refrigerated Packaging for £7.50.
Wool cool keeps pharmaceutical products at fridge-like, ambient, or even freezing temperatures for up to 72 hours, and possibly longer depending on the contents and use of ice packs.
Important Delivery Information:
- Receipt Required: Someone must be available to receive the delivery. Woolcool packaging is designed for temperature-controlled goods, so parcels cannot be left unattended.
- Immediate Refrigeration: Upon receipt, refrigerate the contents immediately to ensure your food or medicine remains at the correct temperature.
- Failed Delivery Attempts: We are not responsible for the cost of replacements if a delivery attempt fails due to the absence of someone to receive it.
We want you to be completely satisfied with any purchase. If not any item* can be returned to us within 14 days of receipt for exchange or refund Please give us a ring for a returns number on 01833 641112 or alternatively email sales@hyperdrug.co.uk to obtain a returns number.
*Due to legal requirements medicines may not be returned except to correct an error in despatch or in response to an "official recall". If an item is believed to be faulty it should be returned for inspection and it may be necessary to forward it to the manufacturers for testing before replacements or refunds can be authorised. This does not infringe legal rights. Please contact our customer services for a "Returns Number" which must appear on the outside of the package or it will not be accepted. We advise customers to use an insured method of shipping and to retain proof of despatch. We may refuse returns on products specially obtained or manufactured to order. Items must be returned unsoiled and unused and sent adequately packed and carriage paid.
